Effects of Treatment on Angiogenic (Vascular Endothelial Growth Factor-2 and Matrix Metalloproteinase-2) and Antiangiogenic (Endostatin and Thrombospondin-1) Factors in Non-muscle Invasive Bladder Carcinoma

KOSOVA, FUNDA; Üçer, Oktay; ARI, Zeki; MÜEZZINOGLU, TALHA; TEMELTAŞ, Gökhan

Effects of Treatment on Angiogenic (Vascular Endothelial Growth Factor-2 and Matrix Metalloproteinase-2) and Antiangiogenic (Endostatin and Thrombospondin-1) Factors in Non-muscle Invasive Bladder Carcinoma

Gökhan TEMELTAŞ, (Celal Bayar University)

Funda KOSOVA, (Celal Bayar University)

Oktay ÜÇER, (Celal Bayar University)

Talha MÜEZZİNOĞLU, (Celal Bayar University)

Zeki ARI (Celal Bayar University)

Journal of Urological Surgery

0 0

Yıl: 2017 Cilt: 4 Sayı: 2 Sayfa Aralığı: 71 - 75 Metin Dili: Türkçe İndeks Tarihi: 29-07-2022

Effects of Treatment on Angiogenic (Vascular Endothelial Growth Factor-2 and Matrix Metalloproteinase-2) and Antiangiogenic (Endostatin and Thrombospondin-1) Factors in Non-muscle Invasive Bladder Carcinoma

Öz:

Amaç: Kas invaziv olmayan mesane kanserinde (KİOMK) tedavinin anjiyogenik [vasküler endotelyal büyüme faktörü-2 (VEGF-2) ve matriks metaloproteinaz-2 (MMP-2)] ve antianjiyogenik [endostatin (ES) and trombospondin-1 (TSP-1)] faktörler üzerine etkilerini araştırmayı amaçladık.Gereç ve Yöntem: KİOMK'li 30 hasta ve aynı yaş grubundaki 30 kontrol çalışmaya dahil edildi. Hastaların kan örnekleri üç defa alınarak yukarıda bahsedilen markerlar enzime bağlı immünosorbent testi yöntemiyle ölçüldü. İlk kan örneği transüretral rezeksiyon-mesane tümörü (TUR-MT) öncesi, ikinci örnek TUR-MT sonrası 20. günde ve son örnek intravezikal immünoterapi sonrası alındı. Hasta ve kontrol grubunun marker ölçüm ortalamaları karşılaştırıldı. Ayrıca hasta grubundan alınan üç ayrı ölçüm de kendi arasında karşılaştırıldı.Bulgular: Hasta grubunun TRU-MT öncesi ortalama VEGF-2 ve MMP-2 değerleri kontrol grubununkinden anlamlı olarak yüksel bulunurken (sırasıyla p=0,04 ve p=0,01), ortalama ES ve TSP-1 değerleri iki grup arasında istatistiksel olarak benzerdi (sırasıyla p=0,95 ve p=0,99). VEGF-2 ve MMP-2 değerlerinin hasta grubunda TUR-MT sonrası anlamlı olarak azaldığı saptanırken (sırasıyla p=0,03 ve p=0,01), bu azalma intravezikal tedavi sonrası devam etmekle birlikte istatistiksel olarak anlamsızdı. Sonuç: KİOMK'li hastalardaki yüksek VEGF-2 ve MMP-2 değerleri TUR-MT sonrası muhtemel kitlenin alınmasına bağlı olarak azalmaktadır. Bu anjiyogenik markerlar KİOMK tedavi sonrası takipte kullanılabilir

Anahtar Kelime:

Konular: Tıbbi Araştırmalar Deneysel Genel ve Dahili Tıp Üroloji ve Nefroloji Hematoloji

Kas İnvaziv Olmayan Mesane Kanserinde Tedavinin Anjiyogenik (Vasküler Endotelyal Büyüme Faktörü-2 ve Matriks Metaloproteinaz-2) ve Antianjiyogenik (Endostatin ve Trombospondin-1) Faktörler Üzerine Etkisi

Öz:

Objective: We aimed to investigate possible effects of treatment on angiogenic [vascular endothelial growth factor-2 (VEGF-2) and matrix metalloproteinase-2 (MMP-2)] and antiangiogenic [endostatin (ES) and thrombospondin-1 (TSP-1)] factors in non-muscle invasive bladder carcinoma (NMIBC). Materials and Methods: Thirty NMIBC patients and 30 age-matched controls were included in the study. For the above-mentioned markers, peripheral blood samples were drawn at three time points to be studied by enzyme-linked immunosorbent assay: before transurethral resection of bladder tumor (TURBT), at first control (20 days after the operation) and second control (at the end of intravesical immunotherapy). The mean blood levels obtained in the three measurements and those in patients and controls were compared statistically.Results: The mean levels of VEGF-2 and MMP-2 in patients before TURBT were found to be statistically significantly higher than in controls (p=0.04 and p=0.01, respectively), while no significant differences were obtained between the mean ES and TSP-1 levels (p=0.95 and p=0.99, respectively). It was also found that the VEGF-2 and MMP-2 levels were significantly decreased after TURBT (p=0.03 and p=0.01, respectively), but the tendency of these decrease was not found to be statistically significant between the first and second controls. Conclusion: Elevated VEGF-2 and MMP-2 levels in patients with NMIBC were significantly decreased after and probably due to the TURBT, which leads to a conclusion that these angiogenic markers may be used for follow-up of NMIBC

Anahtar Kelime:

Konular: Tıbbi Araştırmalar Deneysel Genel ve Dahili Tıp Üroloji ve Nefroloji Hematoloji

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık

1. Bergers G, Benjamin LE. Tumorigenesis and the angiogenic switch. Nat Rev Cancer 2003;3:401-410.
2. Fauconnet S, Bernardini S, Lascombe I, Boiteux G, Clairotte A, Monnien F, Chabannes E, Bittard H. Expression analysis of VEGF-A and VEGF-B: Relationship with clinicopathological parameters in bladder cancer. Oncol Rep 2009;21:1495-1504.
3. Babjuk M, Burger M, Zigeuner R, Shariat SF, van Rhijn BW, Comperat E, Sylvester RJ, Kaasinen E, Böhle A, Palou Redorta J, Roupret M; European Association of Urology. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update, 2013. Eur Urol 2013;64:639-653.
4. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1995;1:27-31.
5. Donmez G, Sullu Y, Baris S, Yildiz L, Aydin O, Karagoz F, Kandemir B. Vascular endothelial growth factor (VEGF), matrix metalloproteinase-9 (MMP-9), and thrombospondin-1 (TSP-1) expression in urothelial carcinomas. Pathol Res Pract 2009;205:854-857.
6. Stavropoulos NE, Bouropoulos C, Ioachim IE, Michael M, Hastazeris K, Tsimaris I, Kalogeras D, Liamis Z, Stefanaki S, Agnantis NI. Prognostic significance of angiogenesis in superficial bladder cancer. Int Urol Nephrol 2004;36:163-167.
7. Szarvas T, László V, Vom Dorp F, Reis H, Szendröi A, Romics I, Tilki D, Rübben H, Ergün S. Serum endostatin levels correlate with enhanced extracellular matrix degradation and poor patients’ prognosis in bladder cancer. Int J Cancer 2012;130:2922-2929.
8. Schmidt A, Sommer F, Reiner M, Klotz T, Engelmann U, Addicks K, Bloch W. Differential endostatin binding to bladder, prostate and kidney tumour vessels. BJU Int 2005;95:174-179.
9. Szarvas T, Jäger T, Droste F, Becker M, Kovalszky I, Romics I, Ergün S, Rübben H. Serum levels of angiogenic factors and their prognostic relevance in bladder cancer. Pathol Oncol Res 2009;15:193-201.
10. Nakanishi R, Oka N, Nakatsuji H, Koizumi T, Sakaki M, Takahashi M, Fukumori T, Kanayama HO. Effect of vascular endothelial growth factor and its receptor inhibitor on proliferation and invasion in bladder cancer. Urol Int 2009;83:98-106.
11. Bernardini S, Fauconnet S, Chabannes E, Henry PC, Adessi G, Bittard H. Serum levels of vascular endothelial growth factor as a prognostic factor in bladder cancer. J Urol 2001;166:1275-1279.
12. Rodriguez Faba O, Palou-Redorta J, Fernández-Gomez JM, Algaba F, Eiro N, Villavicencio H, Vizoso FJ. Matrix Metalloproteinases and Bladder Cancer: What is New? ISRN Urol 2012;2012:581539.
13. Staack A, Badendieck S, Schnorr D, Loening SA, Jung K. Combined determination of plasma MMP2, MMP9, and TIMP1 improves the noninvasive detection of transitional cell carcinoma of the bladder. BMC Urol 2006;6:19.
14. Gohji K, Fujimoto N, Komiyama T, Fujii A, Ohkawa J, Kamidono S, Nakajima M. Elevation of serum levels of matrix metalloproteinase-2 and -3 as new predictors of recurrence in patients with urothelial carcinoma. Cancer 1996;78:2379-2387.

APA	TEMELTAŞ G, KOSOVA F, Üçer O, MÜEZZINOGLU T, ARI Z (2017). Effects of Treatment on Angiogenic (Vascular Endothelial Growth Factor-2 and Matrix Metalloproteinase-2) and Antiangiogenic (Endostatin and Thrombospondin-1) Factors in Non-muscle Invasive Bladder Carcinoma. , 71 - 75.
Chicago	TEMELTAŞ Gökhan,KOSOVA FUNDA,Üçer Oktay,MÜEZZINOGLU TALHA,ARI Zeki Effects of Treatment on Angiogenic (Vascular Endothelial Growth Factor-2 and Matrix Metalloproteinase-2) and Antiangiogenic (Endostatin and Thrombospondin-1) Factors in Non-muscle Invasive Bladder Carcinoma. (2017): 71 - 75.
MLA	TEMELTAŞ Gökhan,KOSOVA FUNDA,Üçer Oktay,MÜEZZINOGLU TALHA,ARI Zeki Effects of Treatment on Angiogenic (Vascular Endothelial Growth Factor-2 and Matrix Metalloproteinase-2) and Antiangiogenic (Endostatin and Thrombospondin-1) Factors in Non-muscle Invasive Bladder Carcinoma. , 2017, ss.71 - 75.
AMA	TEMELTAŞ G,KOSOVA F,Üçer O,MÜEZZINOGLU T,ARI Z Effects of Treatment on Angiogenic (Vascular Endothelial Growth Factor-2 and Matrix Metalloproteinase-2) and Antiangiogenic (Endostatin and Thrombospondin-1) Factors in Non-muscle Invasive Bladder Carcinoma. . 2017; 71 - 75.
Vancouver	TEMELTAŞ G,KOSOVA F,Üçer O,MÜEZZINOGLU T,ARI Z Effects of Treatment on Angiogenic (Vascular Endothelial Growth Factor-2 and Matrix Metalloproteinase-2) and Antiangiogenic (Endostatin and Thrombospondin-1) Factors in Non-muscle Invasive Bladder Carcinoma. . 2017; 71 - 75.
IEEE	TEMELTAŞ G,KOSOVA F,Üçer O,MÜEZZINOGLU T,ARI Z "Effects of Treatment on Angiogenic (Vascular Endothelial Growth Factor-2 and Matrix Metalloproteinase-2) and Antiangiogenic (Endostatin and Thrombospondin-1) Factors in Non-muscle Invasive Bladder Carcinoma." , ss.71 - 75, 2017.
ISNAD	TEMELTAŞ, Gökhan vd. "Effects of Treatment on Angiogenic (Vascular Endothelial Growth Factor-2 and Matrix Metalloproteinase-2) and Antiangiogenic (Endostatin and Thrombospondin-1) Factors in Non-muscle Invasive Bladder Carcinoma". (2017), 71-75.

APA	TEMELTAŞ G, KOSOVA F, Üçer O, MÜEZZINOGLU T, ARI Z (2017). Effects of Treatment on Angiogenic (Vascular Endothelial Growth Factor-2 and Matrix Metalloproteinase-2) and Antiangiogenic (Endostatin and Thrombospondin-1) Factors in Non-muscle Invasive Bladder Carcinoma. Journal of Urological Surgery, 4(2), 71 - 75.
Chicago	TEMELTAŞ Gökhan,KOSOVA FUNDA,Üçer Oktay,MÜEZZINOGLU TALHA,ARI Zeki Effects of Treatment on Angiogenic (Vascular Endothelial Growth Factor-2 and Matrix Metalloproteinase-2) and Antiangiogenic (Endostatin and Thrombospondin-1) Factors in Non-muscle Invasive Bladder Carcinoma. Journal of Urological Surgery 4, no.2 (2017): 71 - 75.
MLA	TEMELTAŞ Gökhan,KOSOVA FUNDA,Üçer Oktay,MÜEZZINOGLU TALHA,ARI Zeki Effects of Treatment on Angiogenic (Vascular Endothelial Growth Factor-2 and Matrix Metalloproteinase-2) and Antiangiogenic (Endostatin and Thrombospondin-1) Factors in Non-muscle Invasive Bladder Carcinoma. Journal of Urological Surgery, vol.4, no.2, 2017, ss.71 - 75.
AMA	TEMELTAŞ G,KOSOVA F,Üçer O,MÜEZZINOGLU T,ARI Z Effects of Treatment on Angiogenic (Vascular Endothelial Growth Factor-2 and Matrix Metalloproteinase-2) and Antiangiogenic (Endostatin and Thrombospondin-1) Factors in Non-muscle Invasive Bladder Carcinoma. Journal of Urological Surgery. 2017; 4(2): 71 - 75.
Vancouver	TEMELTAŞ G,KOSOVA F,Üçer O,MÜEZZINOGLU T,ARI Z Effects of Treatment on Angiogenic (Vascular Endothelial Growth Factor-2 and Matrix Metalloproteinase-2) and Antiangiogenic (Endostatin and Thrombospondin-1) Factors in Non-muscle Invasive Bladder Carcinoma. Journal of Urological Surgery. 2017; 4(2): 71 - 75.
IEEE	TEMELTAŞ G,KOSOVA F,Üçer O,MÜEZZINOGLU T,ARI Z "Effects of Treatment on Angiogenic (Vascular Endothelial Growth Factor-2 and Matrix Metalloproteinase-2) and Antiangiogenic (Endostatin and Thrombospondin-1) Factors in Non-muscle Invasive Bladder Carcinoma." Journal of Urological Surgery, 4, ss.71 - 75, 2017.
ISNAD	TEMELTAŞ, Gökhan vd. "Effects of Treatment on Angiogenic (Vascular Endothelial Growth Factor-2 and Matrix Metalloproteinase-2) and Antiangiogenic (Endostatin and Thrombospondin-1) Factors in Non-muscle Invasive Bladder Carcinoma". Journal of Urological Surgery 4/2 (2017), 71-75.